Company news
Neuphoria Therapeutics Inc. news in 2022
Neuphoria Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
December 17, 2022
Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer
December 14, 2022
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
December 1, 2022
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
November 20, 2022
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
November 15, 2022
Bionomics Limited to Participate in Upcoming November Investor Conferences
November 1, 2022
Quarterly Activities Report for September 2022
October 24, 2022
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
October 17, 2022
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
October 3, 2022
Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder
September 20, 2022
Bionomics to Participate in Upcoming September Investor Conferences
August 30, 2022
Bionomics reports Full Year Financial Results
August 24, 2022
Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
August 7, 2022
Quarterly Activities Report for June 2022
July 28, 2022
Bionomics to Participate in William Blair’s Biotech Focus Conference 2022
July 7, 2022
Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference
June 26, 2022
Bionomics Investor Webinar
June 12, 2022
Bionomics Limited to Participate in Upcoming Investor Conferences
May 15, 2022
Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
May 9, 2022
Bionomics' Half-Year Report
February 22, 2022
Bionomics Limited participated in the H.C Wainwright BioConnect Conference
January 11, 2022
Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs in the United States
January 4, 2022
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
January 2, 2022
Decks in 2022
- Bionomics — H.C. Wainwright BIOCONNECT Virtual Conference 2022
Conference · 37 slides · Jan 12, 2022